Note: EPS may not be comparable

Aclaris Therapeutics (NASDAQ: ACRS) reported Q4 EPS of ($0.74), $0.17 better than the analyst estimate of ($0.91). Revenue for the quarter came in at $1 million versus the consensus estimate of $520 thousand.

2018 Financial Outlook

• Aclaris expects 2018 GAAP research and development (R&D) expenses to be in the range of $67 to $75 million, which, when excluding estimated stock-based compensation of $9 million, results in 2018 non-GAAP R&D expense of $58 to $66 million. The anticipated increase in R&D expenses in 2018 is mainly due to the planned execution of Phase 2 clinical trials in AA, AGA, and vitiligo, two planned pivotal Phase 3 trials in common warts, and development of our early stage pipeline compounds.
• Aclaris expects 2018 GAAP selling, general and administrative (SG&A) expenses to be in the range of $80 to $86 million, which, when excluding estimated stock-based compensation of $14 million, results in 2018 non-GAAP SG&A expense of $66 to $72 million. The anticipated increase in SG&A expenses in 2018 is primarily the result of the deployment of our new sales force in January 2018 and the additional selling, marketing and consumer initiatives to support the commercial launch of ESKATA.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.